Novartis touts latest Zolgensma data as SMA competition against Biogen, Roche heats up

As Roche's new spinal muscular atrophy (SMA) drug, Evresdi, gains steam, Novartis is hoping some new trial data can help its gene therapy Zolgensma stand out in the increasingly competitive field.

In phase 3 data from the SPR1NT study presented at the European Academy for Neurology virtual congress, Zolgensma met its primary and secondary goals of helping patients sit independently for at least 30 seconds and helping them survive to 14 months of age without mechanical help breathing.